REG - Syncona Limited - Anaveon to present clinical data update

SynconaAnnouncement

16/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231016:nRSP1387Qa&default-theme=true

RNS Number : 1387Q  Syncona Limited  16 October 2023

Syncona Limited

 

Anaveon to present clinical data update

 

 

16 October 2023

 

Syncona Ltd, a leading healthcare company focused on creating, building and
scaling a portfolio of global leaders in life science, notes that its
portfolio company, Anaveon, has announced that it will present updated
clinical data from the ongoing Phase I dose escalation study of ANV419 in
patients with solid tumours in a poster at the European Society of Medical
Oncology (ESMO) annual meeting. ANV419 is a selective interleukin-2 (IL-2)
agonist, a type of protein which has the potential to therapeutically enhance
a patient's immune system to respond to tumours. It has been designed to
overcome known challenges with approved IL-2 therapies and enable the delivery
of high dose IL-2 to patients in a way which addresses safety, tolerability
and durability issues seen elsewhere in its use.

 

Highlights from the poster presentation include:

 

·   Overall, ANV419 continues to demonstrate a potentially differentiated
safety profile to approved IL-2 therapies

·      ANV419, at a dose of 243 µg/kg every two weeks, was determined
as the recommended Phase II dose

·    The study determined that one injection of ANV419 at this dose level
delivers more IL-2 exposure than a full cycle of an approved IL-2 therapy
(high dose aldesleukin)

·    A durable response was observed in one patient with advanced
immunotherapy-resistant non-small cell lung cancer (NSCLC)

·     Details of the poster are copied below, with further detail
available in the abstract on the ESMO website
(https://www.esmo.org/meeting-calendar/esmo-congress-2023)

 

Martin Murphy, Chair of Syncona Investment Management Limited, said: "The data
which will be presented at ESMO further underlines the strong safety and
tolerability profile of ANV419, demonstrating potential differentiation from
other IL-2 therapies. We are encouraged by the NSCLC patient who has
demonstrated a durable response and now await the full efficacy read-out in
the ongoing monotherapy trial in melanoma at the recommended Phase II
dose."

 

Poster # 1031P: ANV419, a selective IL-2Rβ/γ agonist in patients with
relapsed/refractory advanced solid tumours

Authors: E. Calvo, M. Joerger, H. Läubli, J. Lopez, G. Alonso Casal, E.
Corral, D. Hess, D. König, V. S. Perez, E. Gasal, S. Jethwa, D. Di Blasi, E.
Garralda

Date and Time: Monday, October 23, 2023, at 11:00am-12:00pm BST / 12:00pm-1:00
pm (CEST),

 

The accompanying poster will be on display on the ESMO 2023 meeting platform
as well as on Anaveon's website from October 23, 2023.

 

The announcement can be accessed on Anaveon's website at
https://anaveon.com/news/ (https://anaveon.com/news/) and the full text of the
announcement from Anaveon is contained below.

 

Enquiries

 

Syncona Ltd

 

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

 

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.

 

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading life
science businesses, across development stage, modality and therapeutic areas,
for the benefit of all our stakeholders. We focus on developing treatments for
patients by working in close partnership with world-class academic founders
and management teams. Our balance sheet underpins our strategy enabling us to
take a long-term view as we look to improve the lives of patients with no or
poor treatment options, build sustainable life science companies and deliver
strong risk-adjusted returns to shareholders.

 

 

 

Anaveon announces poster presentation at the 2023 European Society for Medical
Oncology Annual Meeting

 

- ANV419 243 µg/kg selected as recommended Phase 2 dose for solid tumors -

 

 

Basel, October 16, 2023 - Anaveon, a clinical stage, immuno-oncology company,
today announced that it will present a poster on its lead program ANV419 at
the European Society of Medical Oncology (ESMO) annual meeting being held from
Friday October 20, 2023, to Tuesday, October 24, 2023, in Madrid, Spain.

 

ANV419 is a potent and selective IL-2Rβ/γ agonist, designed to enable the
delivery of high-dose IL-2 to patients in a safe way. ANV419-001 is a
first-in-human, Phase 1 dose escalation study of intravenous single agent
ANV419 in patients with advanced solid tumors. Overall, ANV419 was
well-tolerated, with all events being self-limiting, reversible, or manageable
with standard supportive care. ANV419, at a dose of 243 µg/kg every two weeks
(Q2W), was determined as the maximum tolerated dose (MTD) and the recommended
Phase 2 dose (RP2D). At this dose, PK modeling shows that one injection of
ANV419 delivers more IL-2 exposure than a full cycle of high dose aldesleukin.

 

The abstract is available on the ESMO
(https://www.esmo.org/meeting-calendar/esmo-congress-2023)
(https://www.esmo.org/meeting-calendar/esmo-congress-2023) website
(https://www.esmo.org/meeting-calendar/esmo-congress-2023) , and the
accompanying poster will be on display on the ESMO 2023 meeting platform as
well as on Anaveon's website (https://anaveon.com/publications/) from October
23, 2023.

 

Poster # 1031P - ANV419, a selective IL-2Rβ/γ agonist in patients with
relapsed/refractory advanced solid tumors

Authors: E. Calvo, M. Joerger, H. Läubli, J. Lopez, G. Alonso Casal, E.
Corral, D. Hess, D. König, V. S. Perez, E. Gasal, S. Jethwa, D. Di Blasi, E.
Garralda

 

The Poster will be presented on Monday, October 23, 2023, between 12:00 pm and
1:00 pm (CEST).

 

Anaveon is developing selective cytokine receptor agonists with the potential
to therapeutically enhance a patient's immune system to respond to tumors.
ANV419, currently in Phase 2 studies in multiple cancer indications, is
designed to preferentially signal through the IL-2 beta/gamma receptor
resulting in strong proliferation of effector cells in patients.  The
follow-on compound, ANV600, targets the selective IL-2 receptor moiety to
tumor infiltrating lymphocytes cells and may have therapeutic benefit in less
immunogenic tumors. These novel types of therapeutics, if approved, could
potentially have a wide utility in oncology, including in combination with
cell therapies, vaccines, checkpoint inhibitors and radiotherapy.

ENDS

 

Enquiries

JW Communications

Julia Wilson

Email: Julia.Wilson@anaveon.com (mailto:Julia.wilson@anaveon.com)

Tel: +44 7818 430877

About Anaveon

Anaveon is a clinical stage, biopharmaceutical company, based in Switzerland,
that develops biologics to modulate the function of cytokines and provide
substantial therapeutic benefit to cancer patients.  Our vision is to develop
novel immune therapies benefiting patients suffering from a wide variety of
diseases with immune pathology. For further information please visit the
Company's website at: www.anaveon.com (http://www.anaveon.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUFLFERIVLVLIV